204 ZEB2 Acts As a Crucial Transcriptional Regulator Governing Age- Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus

Sheng Chen,Nan Shen,Yang Jiang,Huihua Ding,Dai,Xiaxia Han,Shuangshuang Gu
DOI: https://doi.org/10.1136/lupus-2023-lupus21century.11
2024-01-01
Abstract:Background/Purpose Age-associated B cells (ABCs) accumulate and contribute to the pathogenesis of systemic autoimmune diseases like lupus. Despite recent insights into the ontogeny and function of ABCs, the key transcriptional regulators of ABCs differentiation remain ill-defined. Addressing this gap in knowledge will reveal targets to enable the prevention or reduction of ABCs in disease therapy. Methods We employed single-cell RNA sequencing to identify transcription factors (TFs) that were differentially expressed in age-associated B cells (ABCs) from both lupus patients and lupus-prone mice. An arrayed CRISPR screen of these regulatory TFs was conducted under in-vitro conditions that induce ABC formation. In our cohort, we included patients diagnosed with Mowat-Wilson Syndrome (MWS), a condition attributed to ZEB2 haploinsufficiency. We constructed B-cell-specific Zeb2 knockout mice and subjected them to TLR7-driving and Bm12-transfer lupus models, enabling us to study Zeb2's regulatory role in ABC formation and associated autoimmunity. The detection of autoantibodies was achieved using an autoantigen microarray. To investigate Zeb2's direct targets, we performed ATAC-seq, Cut & Tag, and Cut & Run sequencing, and integrated these regulome findings with transcriptome data obtained from RNA sequencing. We employed trans-well and PHrodo staining techniques to study the distinct migratory and phagocytic features of ABCs. The induced lupus models were used to evaluate the potential of the JAK1/3 inhibitor tofacitinib in intervening with ABC formation and associated autoimmunity. Results We carried out a screening process and identified that Zeb2 is required for in-vitro differentiation of ABCs in both humans and mice. We observed a reduction in ABCs in individuals with ZEB2 haploinsufficiency and in mice devoid of Zeb2 in B-cells (figure 1). By utilizing mice that selectively lack Zeb2 in B cells, we demonstrated the essential role of Zeb2 in facilitating autoimmune pathology relevant to ABCs, including autoantibody formation, production of proinflammatory cytokines and chemokines, migration to end- organ tissues, and induction of tissue damage in a lupus model (figure 1). Zeb2 binds to the +20kb intronic enhancer of Mef2b, thereby repressing Mef2b-mediated germinal center B-cell differentiation and instead promoting ABC formation (figure 2). Zeb2 also targets genes crucial for ABC specification and function, including Itgax (figure 2). Furthermore, Zeb2 regulates the distinct cellular characteristics of ABCs, including their migration and phagocytic abilities. The differentiation of ABCs driven by Zeb2 necessitates Jak-Stat signaling. Notably, we found that the use of tofacitinib, an approved JAK1/3 inhibitor, effectively reduces the accumulation of ABCs in autoimmune mice and patients (figure 3). Conclusion Our study reveals that ABCs, a unique B cell subset, rely on Zeb2 expression and regulation. Zeb2 affects germinal center B cell development and dictates ABC identity. Modulating Zeb2-mediated Jak-Stat signaling could effectively curb ABC accumulation and related autoimmunity, presenting a potential therapy for autoimmune diseases.
What problem does this paper attempt to address?